Connor, Clark & Lunn Investment Management (CC&L)’s State Street SPDR S&P Pharmaceuticals ETF XPH Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio XPH Stock Details XPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-58,500	Closed	-$2.49M	–	865
2017 Q3	$2.49M	Hold	58,500	–	–	0.01%	384
2017 Q2	$2.52M	Buy	58,500 +37,800	+183%	+$1.59M	0.02%	352
2017 Q1	$866K	Sell	20,700 -300	-1%	-$12.2K	0.01%	513
2016 Q4	$821K	Sell	21,000 -19,900	-49%	-$810K	0.01%	519
2016 Q3	$1.81M	Buy	+40,900	New	+$1.86M	0.01%	378

Other funds holding XPH

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Baird Financial Group Milwaukee, Wisconsin $64B AUM 22.64% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

WBG

Wharton Business Group Malvern, Pennsylvania $2.65B AUM 20.73% 1-Year Est. Return

PVH

Psagot Value Holdings Tel Aviv, Israel $11M AUM 32.09% 1-Year Est. Return

RJA

Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

HCIA

Hochman Cole Investment Advisors Deerfield, Illinois $255M AUM 23.27% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s XPH Position: Q4 2017 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of State Street SPDR S&P Pharmaceuticals ETF (XPH) in Q4 2017, closing a stake of 58,500 shares — an estimated $2.49M sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in XPH in Q3 2016 and held it in 5 quarters. The position peaked at $2.52M in Q2 2017. 85 funds tracked by Wall St. Rank hold XPH as of Q4 2017.

Connor, Clark & Lunn Investment Management (CC&L) reported no remaining State Street SPDR S&P Pharmaceuticals ETF position as of Q4 2017 after selling out during the quarter.
Connor, Clark & Lunn Investment Management (CC&L) sold 58,500 State Street SPDR S&P Pharmaceuticals ETF shares in Q4 2017, an estimated $2.49M.
Connor, Clark & Lunn Investment Management (CC&L) first reported a position in State Street SPDR S&P Pharmaceuticals ETF in Q3 2016 and held it in 5 quarters.
Connor, Clark & Lunn Investment Management (CC&L)'s State Street SPDR S&P Pharmaceuticals ETF position peaked at $2.52M in Q2 2017.
85 funds tracked by Wall St. Rank held State Street SPDR S&P Pharmaceuticals ETF as of Q4 2017.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q4 2017, filed 9 Feb 2018.